Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zapping the brain to stop face pain: new hope for sufferers

NCT ID NCT07352384

Symptom relief Sponsor: Egas Moniz - Cooperativa de Ensino Superior, CRL Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether non-invasive brain stimulation (tDCS or TMS) can reduce chronic orofacial pain—pain in the face, mouth, or jaw that lasts more than 3 months. About 50 adults who haven't gotten enough relief from standard treatments will receive either real stimulation or a sham (placebo) over two weeks. Researchers will measure pain levels, chewing function, and quality of life to see if this approach offers a safe, drug-free option for pain control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: Participants between 18 and 75 years old. * Diagnosis of Chronic Orofacial Pain: Patients with persistent orofacial pain for more than 3 months, confirmed using DC/TMD or other validated diagnostic criteria. * Pain Intensity: Baseline score on the Visual Analogue Scale (VAS) ≥ 4 (moderate to severe pain). * Treatment History: Patients who have previously tried at least one conventional treatment (e.g., medication or physiotherapy) with limited or no success. * Cognitive Ability: Participants cognitively able to understand the study procedures and provide informed consent. * Stable Medication Regimen: Stable chronic pain medication for at least four weeks prior to the intervention. Exclusion Criteria: * Neurological Disorders: History of epilepsy, seizures, or other neurological disorders that contraindicate TMS or tDCS. * Implanted Medical Devices: Presence of pacemakers, cochlear implants, or other electronic/metallic devices in the head or neck region. * Pregnancy: Pregnant or breastfeeding individuals, due to potential risks. * Psychiatric Disorders: Severe psychiatric disorders (e.g., schizophrenia, unstable major depression) that may interfere with study adherence. * Substance Abuse: Current or recent history (within the last 6 months) of alcohol or substance abuse. * Active Medical Conditions: Active infections or untreated systemic diseases that may interfere with results. * TMJ Surgery: History of recent temporomandibular joint surgery or invasive dental procedures (within the last 3 months). * Contraindications for TMS/tDCS: Sensitivity, intolerance, or inability to tolerate the neuromodulation device. * Participation in Another Study: Simultaneous or recent (within the last 3 months) participation in another clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Orofacial pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Chronic Pain Facial Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Orofacial pain

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Egas Moniz School of Health and Science

    Almada, Setúbal District, 2825-148, Portugal

More trials for these conditions

Other studies related to the condition(s) this trial covers.